Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | HINT1 | P49773 | 3/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916016 | 0.85 | LMNA (0.57) | LMNAMTOR | |
| SCHEMBL12104058 | 0.85 | LMNA (0.57) | LMNAMTOR | |
| SCHEMBL7905695 | 0.85 | LMNA (0.57) | LMNAMTOR | |
| SCHEMBL12102510 | 0.85 | LMNA (0.57) | LMNAMTOR | |
| SCHEMBL2101706 | 0.84 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL2101707 | 0.84 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL27811919 | 0.84 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL2101705 | 0.84 | GMNN (0.53) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL7915397 | 0.84 | DNMT1 (0.58) | GMNNALDH1A1LMNATP53NFKB1 | |
| SCHEMBL12102270 | 0.81 | P2RY6 (0.47) | LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | GMNN 4380/4885ALDH1A1 1017/4885LMNA 2696/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | GMNN 3462/4885ALDH1A1 689/4885LMNA 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.